Archival ReportMining Clinical Data for Novel Posttraumatic Stress Disorder Medications
Section snippets
Study Sample and Data Sources
We conducted a nested case-control study within a previously established retrospective cohort that included all VA users with a clinical diagnosis of PTSD (ICD-9 code: 309.81; ICD-10 code: F43.1x) from October 1, 1999, through September 30, 2019 (11). The data source contains information on services use, clinical diagnoses, filled prescriptions, and patient-reported outcome measures (PROMs) for PTSD using the PTSD Checklist (PCL) for these patients. This study was approved by the Veterans
Results
There were 192,912 PCL pairs that met our inclusion criteria, representing 168,941 patients (Table 1). There was a median of 89 days between the baseline and follow-up PCL, with 25% of intervals spanning less than 79 days and 25% of intervals spanning more than 141 days. Cases and controls were similar in terms of demographic and diagnostic characteristics with standardized mean differences of well below 0.1 (Table 2). Cases were more likely to have received EBT and had higher baseline PCL
Discussion
This study is the first large-scale exploration of existing medications that may have potential efficacy for the treatment of PTSD using a population-based sample. There has been limited advancement in the pharmacologic treatment options for PTSD over the last 2 decades, and the findings from this study are an initial step toward future critical innovation in this area. To address this issue, we used a novel exploratory method called TreeScan. Although the application of any novel exploratory
Acknowledgments and Disclosures
This work was supported by the National Institute of Mental Health (Grant No. R01MH121397 [to JLG and BS]). The cohort used for this study was developed through support from the Department of Defense (Grant No. PR160206 [to BS]). The sponsors had no role in the study design, methods, analysis, and interpretation of results or in the preparation of the manuscript and the decision to submit it for publication.
BS was the principal investigator on a Cooperative Research and Development Agreement
References (52)
- et al.
Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions
J Anxiety Disord
(2011) - et al.
It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: A consensus statement of the PTSD Psychopharmacology Working Group
Biol Psychiatry
(2017) - et al.
A collaborative psychopharmacology research agenda for posttraumatic stress disorder
Biol Psychiatry
(2017) - et al.
The prevalence of post-traumatic stress disorder (PTSD) in US combat soldiers: A head-to-head comparison of DSM-5 versus DSM-IV-TR symptom criteria with the PTSD checklist
Lancet Psychiatry
(2014) - et al.
Pharmacological treatment of comorbid PTSD and substance use disorder: Recent progress
Addict Behav
(2014) - et al.
Hepatitis C—new drugs and treatment prospects
Eur J Med Chem
(2019) - et al.
Neurologic manifestations of hepatitis C virus infection
Clin Liver Dis
(2017) - et al.
Biological mechanisms of depression following treatment with interferon for chronic hepatitis C: A critical systematic review
J Affect Disord
(2017) - et al.
Suppression of PKR promotes network excitability and enhanced cognition by interferon-γ-mediated disinhibition
Cell
(2011) - et al.
Amygdala and insula connectivity changes following psychotherapy for posttraumatic stress disorder: A randomized clinical trial
Biol Psychiatry
(2021)